

**PROHLÁŠENÍ AUTORŮ: Prohlášení o původnosti:** Práce je původní a nebyla publikována ani není zaslána k recenznímu řízení do jiného média. **Střet zájmů:** Žádný. **Financování:** Ne. **Poděkování:** N/A. **Registrace v databázích:** N/A. **Projednání etickou komisí:** N/A.

## LITERATURA

1. Yanai H, Adachi H, Hakoshima M, et al. Molecular Biological and Clinical Understanding of the Pathophysiology and Treatments of Hyperuricemia and Its Association with Metabolic Syndrome, Cardiovascular Diseases and Chronic Kidney Disease. *Int J Mol Sci.* 2021;22:9221.
2. El Ridi R, Tallima H. Physiological functions and pathogenic potential of uric acid: A review. *J Adv Res.* 2017;8:487-493.
3. Sorensen LB. Role of the intestinal tract in the elimination of uric acid. *Arthritis Rheum.* 1965;8:694-706.
4. Hisatome I, Ichida K, Mineo I, et al. Guidelines for Management of Hyperuricemia and Gout 3<sup>rd</sup> Edition. *Gout Uric Nucleic Acids.* 2020;44(Supplement):1-40.
5. Merriman TR, Dalbeth N. The genetic basis of hyperuricaemia and gout. *Jt. Bone Spine.* 2011;78:35-40.
6. Simmonds HA, McBride MB, Hatfield PJ, et al. Polynesian women are also at risk for hyperuricaemia and gout because of a genetic defect in renal urate handling. *Br J Rheumatol.* 1994;33:932-937.
7. Dalbeth N, Merriman T. Crystal ball gazing: New therapeutic targets for hyperuricaemia and gout. *Rheumatology.* 2009;48:222-226.
8. Caulfield MJ, Munroe PB, O'Neill D, et al. SLC2A9 is a high-capacity urate transporter in humans. *PLoS Med.* 2008;5:e197.
9. Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. *Nature* 2002;417:447-452.
10. Woodward OM, Köttgen A, Coresh J, et al. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. *Proc Natl Acad Sci.* 2009;106:10338-10342.
11. Li S, Sanna S, Maschio A, et al. The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts. *PLoS Genet.* 2007;3:e194.
12. Vitart V, Rudan I, Hayward C, et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. *Nat Genet.* 2008; 40:437-442.
13. Matsuo H, Takada T, Ichida K, et al. Common defects of ABCG2, a high-capacity urate exporter, cause gout: A function-based genetic analysis in a Japanese population. *Sci Transl Med.* 2009;1:5ra11.
14. Yuan, H.; Yu, C.; Li, X. et al. Serum Uric Acid Levels and Risk of Metabolic Syndrome: A Dose-Response Meta-Analysis of Prospective Studies. *J Clin Endocrinol Metab.* 2015;100:4198-4207.
15. Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. *Am J Med.* 2007;120:442-447.
16. Hjortnaes J, Algra A, Olijhoek J, et al. Serum uric acid levels and risk for vascular diseases in patients with metabolic syndrome. *J Rheumatol.* 2007; 34:1882-1887.
17. Takahashi S, Yamamoto T, Tsutsumi Z, et al. Close correlation between visceral fat accumulation and uric acid metabolism in healthy men. *Metabolism* 1997;46:1162-1165.
18. Facchini F, Chen YD, Hollenbeck CB, et al. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. *JAMA* 1991;266:3008-3011.
19. Wang J, Qin T, Chen J, et al. Hyperuricemia and risk of incident hypertension: A systematic review and meta-analysis of observational studies. *PLoS ONE* 2014;9:e114259.
20. Johnson RJ, Kang DH, Feig D, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? *Hypertension.* 2003;41:1183-1190.
21. Berger L, Yu TF. Renal function in gout. IV. An analysis of 524 gouty subjects including long-term follow-up studies. *Am J Med.* 1975;59:605-613.
22. Feig DI, Madero M, Jalal DI, et al. Uric acid and the origins of hypertension. *J Pediatr.* 2013;162:896-902.
23. Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. *Hypertension.* 2001;38:1101-1106.
24. Uedono H, Tsuda A, Ishimura E, et al. Relationship between serum uric acid levels and intrarenal hemodynamic parameters. *Kidney Blood Press Res* 2015; 40:315-322.
25. Mallat SG, Al Kattar S, Tanius BY, et al. Hyperuricemia, Hypertension, and Chronic Kidney Disease: An Emerging Association *Curr Hypertens Rep.* 2016;18:74.
26. Schröder K, Vecchione C, Jung O, et al. Xanthine oxidase inhibitor tungsten prevents the development of atherosclerosis in ApoE knockout mice fed a Western-type diet. *Free Radic Biol Med.* 2006;41:1353-1360.
27. Ma M, Wang L, Huang W, et al. Meta-analysis of the correlation between serum uric acid level and carotid intima-media thickness. *PLoS ONE* 2021;16:e0246416.
28. Ji X, Leng XY, Dong Y, et al. Modifiable risk factors for carotid atherosclerosis: A meta-analysis and systematic review. *Ann Transl Med.* 2019;7:632.
29. Men P, Punzo G. Uric acid: Bystander or culprit in hypertension and progressive renal disease? *J. Hypertens.* 2008;26:2085-2092.
30. Cheng X, Liu T, Ma L, et al. Prothrombotic effects of high uric acid in mice via activation of MEF2C-dependent NF-κB pathway by upregulating let-7c. *Aging* 2020;12:17976-17989.
31. Yisireyli M, Hayashi M, Wu H, et al. Xanthine oxidase inhibition by febuxostat attenuates stress-induced hyperuricemia, glucose dysmetabolism, and prothrombotic state in mice. *Sci Rep* 2017;7:1266.
32. Nishizawa T, Taniura T, Nomura S. Effects of febuxostat on platelet-derived microparticles and adiponectin in patients with hyperuricemia. *Blood Coagul. Fibrinolysis* 2015;26:887-892.
33. Jia Z, Zhang X, Kang S et al. Serum uric acid levels and incidence of impaired fasting glucose and type 2 diabetes mellitus: A meta-analysis of cohort studies. *Diabetes Res Clin Pract.* 2013;101:88-96.
34. Lv Q, Meng, F, He FF, et al. High serum uric acid and increased risk of type 2 diabetes: A systematic review and meta-analysis of prospective cohort studies. *PLoS ONE* 2013, 8, e56864.
35. Doshi M, Takiue Y, Saito H, et al. The increased protein level of URAT1 was observed in obesity/metabolic syndrome model mice. *Nucleosides Nucleotides Nucleic Acids.* 2011;30:1290-1294.
36. Miao S, Yan S, Wang J, et al. Insulin resistance acts as an independent risk factor exacerbating high-purine diet induced renal injury and knee joint gouty lesions. *Inflamm Res.* 2009;58:659-668.
37. Leyva F, Wingrove CS, Godsland IF, et al. The glycolytic pathway to coronary heart disease: A hypothesis. *Metabolism* 1998;47:657-662.
38. Chen S, Yang H, Chen Y, et al. Association between serum uric acid levels and dyslipidemia in Chinese adults: A cross-sectional study and further meta-analysis. *Medicine.* 2020;99:e19088.
39. Goli P, Riahi R, Daniali SS, et al. Association of serum uric acid concentration with components of pediatric metabolic syndrome: A systematic review and meta-analysis. *J Res Med Sci.* 2020;25:43.
40. Kelishadi R, Mansourian M, Heidari-Beni M. Association of fructose consumption and components of metabolic syndrome in human studies: A systematic review and meta-analysis. *Nutrition.* 2014;30:503-510.
41. Jamnik J, Rehman S, Blanco Mejia S, et al. Fructose intake and risk of gout and hyperuricemia: A systematic review and meta-analysis of prospective cohort studies. *BMJ Open.* 2016;6:e013191.
42. Ng HY, Lee YT, Kuo WH, et al. Alterations of Renal Epithelial Glucose and Uric Acid Transporters in Fructose Induced Metabolic Syndrome. *Kidney Blood Press Res.* 2018;43:1822-1831.
43. Dalbeth N, House ME, Gamble GD, et al. Population-specific influence of SLC2A9 genotype on the acute hyperuricaemic response to a fructose load. *Ann Rheum Dis.* 2013;72:1868-1873.
44. Hallfrisch J. Metabolic effects of dietary fructose. *FASEB J.* 1990; 4:2652-2660.
45. Van den Berghe G. Fructose: Metabolism and short-term effects on carbohydrate and purine metabolic pathways. In *Metabolic Effects of Dietary Carbohydrates*, Macdonald I, Vrana A, Eds, Progress in Biochemical Pharmacology, Karger, Basel, Switzerland, 1986;21:pp.1-32.
46. An Emerging Association. *Curr Hypertens Rep.* 2016;18:74.
47. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCIIT). *Ann Rheum Dis.* 2006;65:1312-1324
48. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. *Arthritis Care Res.* 2012;64:1431-1446
49. Sattui SE, Gaffo AL. Treatment of hyperuricemia in gout: Current therapeutic options, latest developments and clinical implications. *Ther Adv Musculoskelet. Dis* 2016; 8:145-159.
50. Kanbay M, Siritopol D, Nistor I, et al. Effects of allopurinol on endothelial dysfunction: A meta-analysis. *Am J Nephrol.* 2014;39:348-356.
51. Xin W, Mi S, Lin Z. Allopurinol therapy improves vascular endothelial function in subjects at risk for cardiovascular diseases: A meta-analysis of randomized controlled trials. *Cardiovasc Ther.* 2016; 34: 441-449.
52. Cicero AFG, Pirro M, Watts GF, et al. Effects of Allopurinol on Endothelial Function: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. *Drugs* 2018;78:99-109.
53. Alem, M.M. Allopurinol and endothelial function: A systematic review with meta-analysis of randomized controlled trials. *Cardiovasc Ther.* 2018;36:e12432.
54. Zhang T, Pope JE. Cardiovascular effects of urate-lowering therapies in patients with chronic gout: A systematic review and meta-analysis. *Rheumatology* 2017; 56:1144-1153.
55. Bredemeier M, Lopes LM, Eisenreich MA et al. Xanthine oxidase inhibitors for prevention of cardiovascular events: A systematic review and meta-analysis of randomized controlled trials. *BMC Cardiovasc Disord.* 2018;18:24.

Další literatura u autora  
a na [www.casopisvnitrnilekarstvi.cz](http://www.casopisvnitrnilekarstvi.cz)